Keyword: New Enterprise Associates

Vensana Capital has launched with a $225 million fund and ambitions to support new breakthroughs in medical devices, diagnostics and data science.

NEA is making its first investment in Israeli medtech, starting with the developer of a miniaturized blood pump for patients with acute heart failure.

Scott Gottlieb goes back to biotech investing; Seattle Genetics taps first CCO; Affimed parts with CSO; and CSL Behring poaches former Biogen exec.

The funding will advance Inozyme's lead program into clinical trials for rare mineralization disorders in babies and children.

Qpex Biopharma launched as a new infectious disease company, simultaneously obtaining $33 million and preclinical assets from The Medicines Company.

Galera will use the proceeds to start a phase 3 study of GC4419, which seems to prevent severe oral mucositis in patients with head and neck cancers.

Roivant Sciences named NEA partner Frank Torti as Vant investment chair to serve as one of two appointed representatives at its subsidiaries.

The cash sets Intact up to advance a clinical development program designed to generate data to support FDA approval of the Tack Endovascular System.

The device is designed to enable the remote monitoring of heart failure patients and thereby improve outcomes.

Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.